IMARC Group, a leading market research company, has recently releases report titled “Cancer Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global cancer biomarkers market, analysis, trends, share, size, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Cancer Biomarkers Market
Cancer biomarkers are genetic alterations or specific biological molecules that can be found in blood, tissues, urine, or other bodily fluids. They play a pivotal role in the diagnosing and monitoring of cancer. They offer valuable insights into the presence, progression, and response to treatment of cancerous cells. They are utilized by medical professionals for identifying the type and stage of cancer, assess its aggressiveness, and tailor personalized treatment plans for patients. Additionally, cancer biomarkers facilitate the development of targeted therapies and help researchers in clinical trials to assess the efficacy of new treatments.
How Big Is the Cancer Biomarkers Market?
The global cancer biomarkers market size reached US$ 24.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 53.7 Billion by 2028, exhibiting a growth rate (CAGR) of 12.95% during 2023-2028.
Global Industry Trends and Drivers:
Innovations in biomarker discovery, detection, and analysis technologies are driving the development of more accurate and sensitive cancer biomarker tests. This, coupled with the rising prevalence of cancer worldwide, currently represents one of the key factors strengthening the growth of the market. Besides this, the rising shift towards personalized cancer treatment approaches is catalyzing the demand for biomarker-based tests to identify suitable therapies. Favorable reimbursement policies, along with supportive government policies, funding for research, and regulatory approvals, are offering lucrative growth opportunities to industry investors. Apart from this, the growing awareness about cancer screening and early detection programs is influencing the market positively. Furthermore, increasing progress in genomics, proteomics, and metabolomics is projected to fuel the market growth.
What Is Included In Market Segmentation?
The report has been segmented the market into following categories:
Breakup by Profiling Technology:
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics
Breakup by Biomolecule:
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-Biomarkers
Breakup by Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
Breakup by Application:
- Diagnostics
- Prognostics
- Risk Assessment
- Drug Discovery and Development
- Others
Breakup by End User:
- Hospitals
- Academic and Research Institutions
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report provides a comprehensive analysis of the industry key players listed below:
Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Qiagen N.V., Sino Biological Inc. and Thermo Fisher Scientific Inc.
